Ирска - Енглески - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - methotrexate - solution for injection - 500mg/20ml milligram(s)/millilitre - folic acid analogues; methotrexate

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - methotrexate - solution for injection - 50mg/2ml milligram(s)/millilitre - folic acid analogues; methotrexate

Малта - Енглески - Medicines Authority

accord healthcare limited - methotrexate - solution for injection - methotrexate 25 mg/ml - antineoplastic agents

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

accord healthcare limited - methotrexate - solution for injection - 50 milligram(s)/millilitre - other immunosuppressants; methotrexate

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - methotrexate - solution for injection in pre-filled syringe - 50 milligram(s)/millilitre - other immunosuppressants; methotrexate

Малта - Енглески - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - methotrexate - solution for injection - methotrexate 100 milligram(s)/millilitre - antineoplastic agents

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - methotrexate sodium - solution for injection - 25mg/1ml

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - methotrexate sodium - solution for injection - 25mg/1ml

Велика Британија - Енглески - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - methotrexate sodium - solution for injection - 25mg/1ml

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methotrexate, quantity: 500 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - antineoplastic chemotherapy - treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic and meningeal leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemia. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. high dose therapy - the use of very high doses is made possible by vials for injection containing 500 mg and 1000 mg (see precautions). diseases treated with these doses administered in the form of single-drug or combination therapy, include osteogenic sarcoma, acute leukaemia, bronchogenic carcinoma and epidermoid carcinoma of the head and n